The global laser-assisted ENT surgery market Share is projected to grow from US$ 254.14 million in 2023 to US$ 513.78 million ...

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis, chronic rhinosinusitis without ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Most cases of epistaxis in children have benign causes. In a retrospective study3 concerning 175 children younger than 18 years managed for epistaxis in the outpatient ENT clinic of tertiary medical ...

Micro-needling can reduce the appearance of pores GETTY In-office treatments For those seeking more dramatic improvements in pore appearance, professional treatments may help. Fractional laser ...

3 at 2:45 p.m. ET GSK’s IL-5 inhibitor Nucala scored a nod in China to treat people with inadequately controlled chronic rhinosinusitis with nasal polyps ... that it could reduce proteinuria ...